-
Protalix's PRX–102 Monthly Treatment Shows Benefit In Fabry Disease
Tuesday, February 23, 2021 - 8:04am | 313Read More...Protalix BioTherapeutics Inc (NYSE: PLX) and its collaborating partner Chiesi Farmaceutici S.p.A. announced positive topline results from the BRIGHT Phase 3 trial evaluating pegunigalsidase alfa (PRX–102) for the potential treatment of Fabry disease....
-
Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study
Monday, February 8, 2021 - 8:07am | 350Read More...Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction, or complete clearance, of the toxic substrate in the kidney biopsy, was...
-
Amicus Therapeutics Building Rare Disease Treatment Strategy; Bank Of America Initiates At Buy
Wednesday, May 18, 2016 - 9:31am | 252Read More...Bank of America's Peter Stapor initiated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ: FOLD) with a price target of $10.00. The leading drug in the company's portfolio is migalastat (Galafold) for a rare disease (Fabry disease), which results in enzyme deficiency and can lead to organ failure...
-
Amicus Therapeutics Gains 3% On Favorable EU Medicines Recommendation
Friday, April 1, 2016 - 1:37pm | 392Read More...Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD), a bio-pharmaceutical company that focuses on the treatment of rare and orphan diseases, were trading higher by 3 percent Friday afternoon. Amicus Therapeutics announced earlier in the day that the European Committee for Medicinal Products for...
